This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
StoneCo Ltd. (STNE) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
StoneCo (STNE) delivered earnings and revenue surprises of +8.33% and +2.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Match Group (MTCH) Lags Q2 Earnings Estimates
by Zacks Equity Research
Match Group (MTCH) delivered earnings and revenue surprises of -11.11% and +1.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Cellebrite DI Ltd. (CLBT) Tops Q1 Earnings Estimates
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 11.11% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arteris, Inc. (AIP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arteris (AIP) delivered earnings and revenue surprises of 18.18% and 3.98%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CCC Intelligent Solutions Holdings Inc. (CCCS) Meets Q1 Earnings Estimates
by Zacks Equity Research
CCC Intelligent Solutions (CCCS) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
SMGZY or CLBT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SMGZY vs. CLBT: Which Stock Is the Better Value Option?
Priority Technology Skyrockets 227% in a Year: Should You Buy it?
by Arghyadeep Bose
Given the surge in PRTH shares, we evaluate its current position to determine whether investors should jump on the stock's year-old rally.
After Plunging -17.61% in 4 Weeks, Here's Why the Trend Might Reverse for Cellebrite DI Ltd. (CLBT)
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cellebrite DI Ltd. (CLBT) Q4 Earnings Meet Estimates
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AppLovin (APP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AppLovin (APP) delivered earnings and revenue surprises of 29.10% and 8.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cellebrite to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
The surge in subscription filters is likely to have benefited CLBT's top line in the fourth quarter of 2024.
NU or CLBT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NU vs. CLBT: Which Stock Is the Better Value Option?
Cellebrite DI Ltd. (CLBT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 27.27% and 4.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Distribution Solutions Group (DSGR) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Distribution Solutions (DSGR) delivered earnings and revenue surprises of -7.50% and 0.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes Cellebrite DI Ltd. (CLBT) a New Strong Buy Stock
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Retain ENV Stock in Your Portfolio for Now
by Zacks Equity Research
Consistent growth in recurring revenues, and improving efficiency and competitiveness are benefiting Envestnet's performance.
Trane Technologies plc (TT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Trane Technologies (TT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cellebrite DI Ltd. (CLBT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and Nexxen International Ltd. Sponsored ADR (NEXN) have performed compared to their sector so far this year.
Is Exponent (EXPO) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Exponent (EXPO) and Cellebrite DI Ltd. (CLBT) have performed compared to their sector so far this year.
Are Business Services Stocks Lagging Adyen (ADYEY) This Year?
by Zacks Equity Research
Here is how Adyen N.V. Unsponsored ADR (ADYEY) and Cellebrite DI Ltd. (CLBT) have performed compared to their sector so far this year.
Why Cellebrite DI Ltd. (CLBT) Might be Well Poised for a Surge
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cellebrite DI Ltd. (CLBT) and Genpact (G) have performed compared to their sector so far this year.
Cellebrite DI Ltd. (CLBT) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cellebrite DI Ltd. (CLBT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 25% and 4.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?